Subscribe to Pfizer

The Lead

CEO: Pfizer doubles share of drug market for breast cancer

June 4, 2015 11:52 am | by Andy Szal, Digital Reporter | News | Comments

Promising trial results for a new drug designed to treat aggressive breast cancer helped Pfizer double its share of that market, according to CEO Ian Read.

Pfizer offers $3 million in breast cancer grants

May 28, 2015 11:17 am | by Business Wire | News | Comments

The multi-year program, which will award a total of up to $3 million in grants to investigators...

Pfizer Trying To Overcome Patent Cliff

May 20, 2015 10:33 am | News | Comments

Pfizer Inc. is trying to overcome the patent cliff that has seen its recent quarter results...

FTC Seeks More Info From Pfizer About Hospira Acquisition

May 15, 2015 12:04 pm | by Pfizer Inc. | News | Comments

Pfizer Inc. today announced that it has received a request for additional information from the...

View Sample

FREE Email Newsletter

Pfizer Acquires Minority Interest in AM-Pharma

May 12, 2015 11:41 am | by Pfizer | News | Comments

Pfizer recently announced their acquisition of a minority equity interest in AM-Pharma, and secured an exclusive option to acquire the remaining equity in the company.

Pharmaceuticals, Life Sciences Show Dramatic Jump in Merger Activity

May 8, 2015 11:15 am | by Andy Szal, Digital Reporter | News | Comments

The pharmaceuticals and life sciences sectors saw 35 mergers and acquisitions worth $166.3 billion in the first three months of 2015, a value that eclipsed transactions from all of 2014.

A Closer Look at GEA Pharma's Modular Processing Tech

April 28, 2015 11:13 am | by GCONPODs | Videos | Comments

This video showcases the precision engineering involved when GEA Pharma Systems, G-CON and Pfizer collaborated to develop modular, next generation processing technologies for oral solid dosage forms. The technology was recognized at last week's INTERPHEX with an Exhibitor Award.


Pfizer, Despite Obstacles, Delivers Strong Q1 Numbers

April 28, 2015 11:01 am | by The Associated Press | News | Comments

Pfizer overcame patent expirations to beat Wall Street projections for the first quarter, though it cut its outlook for the year.

Pfizer Says Leukemia Drug Met 1 Goal in Study

April 22, 2015 5:03 pm | by The Associated Press | News | Comments

Pfizer said that an experimental blood cancer drug met one of its two goals in a late-stage trial, as patients who were treated with the drug were more likely to have a complete remission.

Pfizer Launches Competitive Grants Program

April 9, 2015 11:16 am | by Pfizer | News | Comments

Pfizer, Inc. is supporting research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease.

Pfizer says Shoppers Drug Mart Acted Quickly on Expired Birth Control Pills

April 8, 2015 11:01 am | by The Canadian Press | News | Comments

The company that manufactures the birth control medication Alesse is giving Shoppers Drug Mart credit for alerting the public that expired pills had been dispensed in the last few weeks.

Study: Zoloft Increased Coronary Atherosclerosis

April 7, 2015 1:19 pm | by Wake Forest Baptist Medical Center | News | Comments

A commonly prescribed antidepressant caused up to a six-fold increase in atherosclerosis plaque in the coronary arteries of non-human primates.


Study: Mixed Picture on Viagra Effectiveness

April 7, 2015 1:15 pm | by University of Manchester | News | Comments

Viagra and other related drugs are not a universal 'cure-all' for impotence, according to a new study from The University of Manchester.

Pfizer Stops China Vaccine Sales as Import License Expires

April 2, 2015 1:45 pm | by The Associated Press | News | Comments

Pfizer has stopped selling its Prevnar 7 pneumonia vaccine in China after its import license expired, but the U.S. drugmaker still intends to launch the world's most widely used vaccine, Prevnar 13, in that market.

Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

March 23, 2015 8:07 am | News | Comments

Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.

Study: Prevnar Vaccine Slashed Serious Infections in Elderly

March 19, 2015 8:33 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

A huge study of Pfizer's blockbuster vaccine against pneumonia and other bacterial infections in adults 65 and older found it protected most of them against dangerous infections in the bloodstream and other sterile body areas.

Ad Industry Group Recommends That Little Remedies Stop Cold, Sore Throat Claims

March 13, 2015 2:22 pm | by Andy Szal, Digital Reporter | News | Comments

The National Advertising Division--an industry regulatory agency administered by the Council of Better Business Bureaus--investigated Prestige Brands Holdings' Little Remedies products following a complaint by Pfizer.


Pfizer Reports Results From A Phase IV Study Evaluating LYRICA® for Adolescents with Fibromyalgia

March 13, 2015 8:07 am | News | Comments

Pfizer has announced top-line results of a double-blind Phase 4 study evaluating the safety and efficacy of Lyrica® (pregabalin) Capsules CV in adolescents (ages 12-17 years) with fibromyalgia (FM).

Pfizer Receives European Approval for New Indication for Prevenar 13

March 3, 2015 8:47 am | News | Comments

Pfizer has announced that the European Commission approved an expanded indication for the use of Prevenar 13 for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older.

Pfizer to Repurchase $5B in Stock in Accelerated Plan

February 10, 2015 8:06 am | News | Comments

The accelerated stock buyback is part of its $11B share repurchase plan authorized in October. It said it will receive the approximately 150 million shares involved in the buyback from Goldman Sachs on Wednesday.       

Analyst: Pfizer’s Acquisition of Hospira Lays Foundation for Potential Generics Unit Spin-Off

February 9, 2015 7:57 am | News | Comments

The Hospira deal will add significant value to Pfizer’s GEP segment, a vertical which has been rumored to be sold or spun-off as a separate entity. This somewhat mirrors Pfizer’s strategic objective to focus on core growth platforms in the branded drug market while divesting its ancillary operations, similar to when it carved-out its Animal Health business and brought it public.

Pfizer Buying Hospira for $15.23B

February 6, 2015 8:02 am | by MICHELLE CHAPMAN, AP Business Writer | News | Comments

Pfizer is buying Hospira for approximately $15.23 billion, saying it is a good fit with its established global pharmaceutical business. The buyout will also help Pfizer tap into the growing market for biosimilars, which are cheaper versions of biologic drugs that are used to treat conditions such as anemia.

Pfizer Receives FDA Accelerated Approval of IBRANCE®

February 4, 2015 3:41 pm | News | Comments

Pfizer anounced the FDA has granted accelerated approval of IBRANCE®, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease.

Pfizer Net Down on Lower Sales, Higher Research, Legal Costs

January 27, 2015 12:53 pm | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Pfizer's fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research spending and legal costs also hurt the bottom line. The world's second-biggest drugmaker by revenue reported lower sales for most of its huge portfolio of prescription medicines, with the biggest hit coming from new generic competition to popular painkiller Celebrex.

Pfizer Beats Wall Street Fourth Quarter Forecasts

January 27, 2015 7:42 am | News | Comments

Pfizer on Tuesday reported fourth-quarter earnings of $1.23B. On a per-share basis, the company said it had net income of 19 cents. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to 54 cents per share.

Pfizer's New Type of Cancer Drug May Get Early OK

January 8, 2015 1:44 pm | by The Associated Press | News | Comments

The first in a new class of cancer medicines, Pfizer's Ibrance, appears poised for approval to treat advanced breast cancer within just a few months and could quickly become a blockbuster, some analysts believe.       

Pfizer Acquires Redvax GmbH

January 5, 2015 8:05 am | News | Comments

Pfizer has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate.

Pfizer Reports Top-Line Results from a Phase III Pain Study

December 18, 2014 10:08 am | News | Comments

Pfizer has announced top-line results from a double-blind Phase III study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherapeutic neuralgia (pain after shingles or PHN).        

Pfizer Starts Phase II Study of PF-06252616 in Duchenne Muscular Dystrophy

December 17, 2014 8:14 am | News | Comments

Pfizer has announced enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.